These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 38802066

  • 1. RUNX1::ETO and CBFβ::MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core-binding factor-acute myeloid leukaemia.
    Wang S, Liu Y, Zhao X, Wang X, Lou J, Jin P, Zhang Y, Yu J, Wang K.
    Br J Haematol; 2024 Aug; 205(2):552-567. PubMed ID: 38802066
    [Abstract] [Full Text] [Related]

  • 2. Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.
    Zhao X, Chen A, Yan X, Zhang Y, He F, Hayashi Y, Dong Y, Rao Y, Li B, Conway RM, Maiques-Diaz A, Elf SE, Huang N, Zuber J, Xiao Z, Tse W, Tenen DG, Wang Q, Chen W, Mulloy JC, Nimer SD, Huang G.
    Blood; 2014 Mar 13; 123(11):1729-38. PubMed ID: 24449215
    [Abstract] [Full Text] [Related]

  • 3. [Clinical features and prognosis of core binding factor acute myeloid leukemia children in South China: a multicenter study].
    Guo BY, Wang Y, Li J, Li CF, Feng XQ, Zheng MC, Liu SX, Yang LH, Jiang H, Xu HG, He XL, Wen H.
    Zhonghua Er Ke Za Zhi; 2023 Oct 02; 61(10):881-888. PubMed ID: 37803854
    [Abstract] [Full Text] [Related]

  • 4. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
    Fischer J, Rossetti S, Datta A, Eng K, Beghini A, Sacchi N.
    Mol Cancer; 2015 Jan 23; 14():7. PubMed ID: 25612891
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia.
    Issa H, Swart LE, Rasouli M, Ashtiani M, Nakjang S, Jyotsana N, Schuschel K, Heuser M, Blair H, Heidenreich O.
    Leukemia; 2023 Apr 23; 37(4):820-834. PubMed ID: 36823395
    [Abstract] [Full Text] [Related]

  • 8. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.
    Ptasinska A, Assi SA, Mannari D, James SR, Williamson D, Dunne J, Hoogenkamp M, Wu M, Care M, McNeill H, Cauchy P, Cullen M, Tooze RM, Tenen DG, Young BD, Cockerill PN, Westhead DR, Heidenreich O, Bonifer C.
    Leukemia; 2012 Aug 23; 26(8):1829-41. PubMed ID: 22343733
    [Abstract] [Full Text] [Related]

  • 9. Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.
    Castilla LH, Bushweller JH.
    Adv Exp Med Biol; 2017 Aug 23; 962():229-244. PubMed ID: 28299661
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation.
    Martinez-Soria N, McKenzie L, Draper J, Ptasinska A, Issa H, Potluri S, Blair HJ, Pickin A, Isa A, Chin PS, Tirtakusuma R, Coleman D, Nakjang S, Assi S, Forster V, Reza M, Law E, Berry P, Mueller D, Osborne C, Elder A, Bomken SN, Pal D, Allan JM, Veal GJ, Cockerill PN, Wichmann C, Vormoor J, Lacaud G, Bonifer C, Heidenreich O.
    Cancer Cell; 2018 Oct 08; 34(4):626-642.e8. PubMed ID: 30300583
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. AML associated oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites to modulate H3ac levels and drive leukemogenesis.
    Singh AA, Mandoli A, Prange KH, Laakso M, Martens JH.
    Oncotarget; 2017 Feb 21; 8(8):12855-12865. PubMed ID: 28030795
    [Abstract] [Full Text] [Related]

  • 14. Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling.
    Pulikkan JA, Madera D, Xue L, Bradley P, Landrette SF, Kuo YH, Abbas S, Zhu LJ, Valk P, Castilla LH.
    Blood; 2012 Jul 26; 120(4):868-79. PubMed ID: 22613795
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.
    Richter LE, Wang Y, Becker ME, Coburn RA, Williams JT, Amador C, Hyde RK.
    Mol Cancer Res; 2019 Jun 26; 17(6):1241-1252. PubMed ID: 30814129
    [Abstract] [Full Text] [Related]

  • 18. RUNX1 and CBFβ-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.
    Zhen T, Cao Y, Ren G, Zhao L, Hyde RK, Lopez G, Feng D, Alemu L, Zhao K, Liu PP.
    Blood; 2020 Nov 19; 136(21):2373-2385. PubMed ID: 32929473
    [Abstract] [Full Text] [Related]

  • 19. A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells.
    Gao XN, Lin J, Ning QY, Gao L, Yao YS, Zhou JH, Li YH, Wang LL, Yu L.
    PLoS One; 2013 Nov 19; 8(2):e55481. PubMed ID: 23390536
    [Abstract] [Full Text] [Related]

  • 20. Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11.
    Hyde RK, Kamikubo Y, Anderson S, Kirby M, Alemu L, Zhao L, Liu PP.
    Blood; 2010 Feb 18; 115(7):1433-43. PubMed ID: 20007544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.